Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016939 · ClinicalTrials.gov registry record · Phase 2
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase 2 study of Kidney Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00016939: Completed Phase 2 study of Kidney Cancer, sponsored by SWOG Cancer Research Network.
NCT00016939 is a Phase 2 study of Kidney Cancer that has completed, run by SWOG Cancer Research Network. The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016939, a Phase 2 study of Kidney Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable or metastatic kidney cancer.
Conditions Studied
Interventions
- DRUG alvocidib
Study Locations (20)
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Veterans Affairs Medical Center - West Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Cancer Center - Sacramento
- University of California Davis Medical Center - Sacramento
- Veterans Affairs Medical Center - San Francisco - San Francisco
- UCSF Cancer Center and Cancer Research Institute - San Francisco
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
Arizona
- CCOP - Greater Phoenix - Phoenix
- Veterans Affairs Medical Center - Phoenix (Hayden) - Phoenix
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center - Tucson
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- MBCCOP - Gulf Coast - Mobile
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-05 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00016939 record still lists
NCT00016939 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which alvocidib is the first listed.
NCT00016939 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00016939 about?
NCT00016939 is a clinical study titled "Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable or metastatic kidney cancer.
What is the current status of trial NCT00016939?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-05. Estimated completion is 2006-04.
What conditions does trial NCT00016939 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00016939?
The interventions under investigation include: alvocidib (DRUG).
Who is sponsoring clinical trial NCT00016939?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00016939 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia